Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 19-20/2016

01.10.2016 | original article

Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives

verfasst von: MD, PhD Prof. Dr. Metin Basaranoglu, Billur Canbakan, Kemal Yildiz, Bahadir Ceylan, Birol Baysal, Omer Uysal, Hakan Senturk

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Fatty liver is a common disease in developed countries. We investigated the frequency of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives.

Methods

In this study, we evaluated 105 patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD), 121 patients with hepatitis C (61 patients with fatty liver and 60 patients without fatty liver), 50 patients with inflammatory bowel disease (IBD), and 109 patients with dyspepsia as a control group.

Results

There was no difference for sex, mean age, and marital status among the groups, except that patients with IBD were younger than others (p < 0.001). The frequency of cancer in family was as follows: 18 % in IBD, 9 % in dyspepsia, 28 % in hepatitis C with hepatic steatosis, 21.5 % in hepatitis C without steatosis, and 27 % in NAFLD (p = 0.006). Then, we divided the study group into two groups—group 1: IBD + dyspepsia + hepatitis C without hepatic steatosis, and group 2: hepatitis C with hepatic steatosis + NAFLD—and performed the same analysis. We found that the frequency of cancer in family was 16 % in group 1 (the patients without fatty liver) vs. 24.4 % in group 2 (those with fatty liver; p = 0.037). We also investigated the rate of operation in patients. The results were as follows: 33 % in group 1 vs. 43 % in group 2 (p = 0.043).

Conclusions

Independently of the underlying chronic diseases, occurrence of fat in the liver increased the frequency of operation in patients with fatty liver and the rate of cancer in their first-degree relatives. Understanding the underlying causes of fatty liver forms might decrease the cancer frequency in the population and number of operation in patients with fatty liver.
Literatur
1.
Zurück zum Zitat Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23. PMID:12668987. doi:10.1053/jhep.2003.50161. CrossRefPubMed Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23. PMID:12668987. doi:10.1053/jhep.2003.50161. CrossRefPubMed
2.
Zurück zum Zitat Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9. PMID:10051466. doi:10.1002/hep.510290347. CrossRefPubMed Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664–9. PMID:10051466. doi:10.1002/hep.510290347. CrossRefPubMed
3.
Zurück zum Zitat Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis. 2004;8:639–71. PMID:15331068. CrossRefPubMed Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis. 2004;8:639–71. PMID:15331068. CrossRefPubMed
4.
Zurück zum Zitat Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16(18):2223–6. PMID:20458758. CrossRefPubMedPubMedCentral Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16(18):2223–6. PMID:20458758. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Basaranoglu M, Turhan N, Sonsuz A, Basaranoglu G. Mallory-Denk bodies in chronic hepatitis. World J Gastroenterol. 2011;17(17):2172–7. PMID:21633525. doi:10.3748/wjg.v17.i17.2172. CrossRefPubMedPubMedCentral Basaranoglu M, Turhan N, Sonsuz A, Basaranoglu G. Mallory-Denk bodies in chronic hepatitis. World J Gastroenterol. 2011;17(17):2172–7. PMID:21633525. doi:10.3748/wjg.v17.i17.2172. CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Canbakan B, Senturk H, Canbakan M, Toptas T, Tuncer M. Reliability of caspase activity as a biomarker of hepatic apoptosis in nonalcoholic fatty liver disease. Biomark Med. 2011;5:813–5. PMID:22103615. CrossRefPubMed Canbakan B, Senturk H, Canbakan M, Toptas T, Tuncer M. Reliability of caspase activity as a biomarker of hepatic apoptosis in nonalcoholic fatty liver disease. Biomark Med. 2011;5:813–5. PMID:22103615. CrossRefPubMed
7.
Zurück zum Zitat Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D’Agostino RB, Gaziano JM, Vasan RS. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation. 2007;116:480–8. CrossRefPubMed Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, D’Agostino RB, Gaziano JM, Vasan RS. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation. 2007;116:480–8. CrossRefPubMed
8.
Zurück zum Zitat Marchesini G, Ridolfi V, Nepoti V. Hepatotoxicity of fast food? Gut. 2008;57:568–70. PMID:18408097. doi:10.1136/gut.2007.143958. CrossRefPubMed Marchesini G, Ridolfi V, Nepoti V. Hepatotoxicity of fast food? Gut. 2008;57:568–70. PMID:18408097. doi:10.1136/gut.2007.143958. CrossRefPubMed
9.
Zurück zum Zitat Basaranoglu M, Sonsuz A, Senturk H, Akin P. The low incidence of primary liver disease in patients with nonalcoholic steatohepatitis. J Hepatol. 2001;35(5):684–5. PMID:11690720. CrossRefPubMed Basaranoglu M, Sonsuz A, Senturk H, Akin P. The low incidence of primary liver disease in patients with nonalcoholic steatohepatitis. J Hepatol. 2001;35(5):684–5. PMID:11690720. CrossRefPubMed
10.
Zurück zum Zitat Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:987–95. PMID:18772365. doi:10.1152/ajpgi.90272.2008. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:987–95. PMID:18772365. doi:10.1152/ajpgi.90272.2008.
11.
Zurück zum Zitat Neuschwander-Tetri BA, Ford DA, Acharya S, Gilkey G, Basaranoglu M, Tetri LH, Brunt EM. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids. 2012;47(10):941–50. CrossRefPubMedPubMedCentral Neuschwander-Tetri BA, Ford DA, Acharya S, Gilkey G, Basaranoglu M, Tetri LH, Brunt EM. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids. 2012;47(10):941–50. CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Sonsuz A, Basaranoglu M, Bilir M, Senturk H, Akin P. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2002;97:495. PMID:11866302. Sonsuz A, Basaranoglu M, Bilir M, Senturk H, Akin P. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2002;97:495. PMID:11866302.
13.
Zurück zum Zitat Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol. 2011;17(36):4055–62. PMID:22039318. Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol. 2011;17(36):4055–62. PMID:22039318.
14.
Zurück zum Zitat Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl. 2011. PMID:22213627. doi:10.1002/prca.201100052. Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl. 2011. PMID:22213627. doi:10.1002/prca.201100052.
15.
Zurück zum Zitat Brunt EM. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis. 2012;30(Suppl. 1):61–8. PMID:23075870. doi:10.1159/000341127. CrossRefPubMed Brunt EM. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis. 2012;30(Suppl. 1):61–8. PMID:23075870. doi:10.1159/000341127. CrossRefPubMed
16.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38. CrossRefPubMed Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38. CrossRefPubMed
17.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. CrossRefPubMed Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. CrossRefPubMed
18.
Zurück zum Zitat Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep. 2010;10:93–100. CrossRefPubMed Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep. 2010;10:93–100. CrossRefPubMed
19.
Zurück zum Zitat Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011;7(7):1003–15. doi:10.7150/ijbs.7.1003. CrossRefPubMedPubMedCentral Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011;7(7):1003–15. doi:10.7150/ijbs.7.1003. CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Basaranoglu M, Neuschwander-Tetri Brent A. Nonalcoholic fatty liver disease: clinical features and pathogenesis. Gastroenterol Hepatol. 2006;2:282–91. Basaranoglu M, Neuschwander-Tetri Brent A. Nonalcoholic fatty liver disease: clinical features and pathogenesis. Gastroenterol Hepatol. 2006;2:282–91.
Metadaten
Titel
Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives
verfasst von
MD, PhD Prof. Dr. Metin Basaranoglu
Billur Canbakan
Kemal Yildiz
Bahadir Ceylan
Birol Baysal
Omer Uysal
Hakan Senturk
Publikationsdatum
01.10.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0744-4